FABP4 and cardiovascular disorder: Recent studies have shown an association between the circulating A-FABP concentration and future cardiovascular disease in patients with end-stage renal disease [10], prevalent coronary heart disease [11], and acute coronary syndrome [12] as well as in a community-based cohort [13].